Princeton, New Jersey, October 27, 2014 – Sandoz, through its branded dermatology business, PharmaDerm, and Medigene AG, today announced the signing of a promotion agreement with Women’s Choice Pharmaceuticals LLC (WCP), a specialty pharmaceutical company based in Gilbert, Arizona, for VEREGEN®(sinecatechins) Ointment, 15%.
VEREGEN® ointment 15% is a topical treatment indicated for external genital or perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
This new promotion agreement aims to expand product sales into the obstetrics, gynecology and urology fields in the United States through increased physician coverage. Throughout the term, PharmaDerm will maintain exclusive promotion rights for dermatologists.
“VEREGEN® is an important part of our PharmaDerm’s portfolio of branded products,” said Peter Goldschmidt, President of Sandoz Inc. “By expanding physician promotion to key clinically relevant physicians, we can increase awareness about this important treatment option.”
PharmaDerm commercializes several branded dermatology products in the United States, including, ApexiCon® E Cream, KERYDIN™, and OXISTAT®.
Important Safety Information
See full prescribing information
Limitations of Use:
Safety and effectiveness of VEREGEN® (sinecatechins) Ointment, 15%, have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses.
WCP will continue to pursue additional opportunities to acquire complementary assets in order to broaden their portfolio and accelerate the Company’s growth.